Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have been given a consensus rating of “Moderate Buy” by the eighteen ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $57.8235.

A number of brokerages have commented on RARE. Morgan Stanley boosted their target price on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a report on Thursday, April 16th. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, July 9th. Wedbush cut their price objective on shares of Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Guggenheim reduced their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company decreased their target price on shares of Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating for the company in a research report on Wednesday.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE opened at $25.82 on Friday. Ultragenyx Pharmaceutical has a 1-year low of $18.29 and a 1-year high of $39.89. The company has a 50-day moving average of $27.85 and a 200 day moving average of $24.79. The firm has a market capitalization of $2.54 billion, a price-to-earnings ratio of -4.42 and a beta of 0.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) EPS for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. The business had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The company’s revenue for the quarter was up 28.5% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.17) EPS. On average, equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.53 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 4,653 shares of Ultragenyx Pharmaceutical stock in a transaction on Monday, June 1st. The shares were sold at an average price of $23.77, for a total transaction of $110,601.81. Following the completion of the sale, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Shehnaaz Suliman sold 5,740 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the completion of the transaction, the director owned 27,951 shares of the company’s stock, valued at $702,129.12. This trade represents a 17.04% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 14,292 shares of company stock valued at $351,644 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors have recently bought and sold shares of the business. Parallel Advisors LLC raised its holdings in shares of Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after purchasing an additional 1,440 shares during the last quarter. Leonteq Securities AG boosted its holdings in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 1,333 shares during the last quarter. Versant Capital Management Inc grew its position in Ultragenyx Pharmaceutical by 662.9% during the 2nd quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 1,001 shares during the period. Danske Bank A S acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth about $39,000. Finally, EverSource Wealth Advisors LLC raised its stake in shares of Ultragenyx Pharmaceutical by 573.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 1,845 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.